URGENT-Ariad suspends sales of blood cancer drug Iclusig

Thursday, 31 Oct 2013 | 7:40 AM ET

Oct 31 (Reuters) - Ariad Pharmaceuticals Inc said it was suspending the sale of its blood cancer drug, Iclusig, barely two weeks after it stopped a late-stage trial of the drug due to safety concerns.

The decision was taken in response to a request by the U.S. Food and Drug Administration on Wednesday afternoon, Ariad said in a statement.

  Price   Change %Change